MLG Publication:

 

Sinclair M, Roberts S, Kemp W, Knight V, Dev A, Gow P, Philpott H, Kronborg I, Arachchi NJ, Bell S, Lim L, Gorelik A, and Nicoll A.   Epidemiology of Hepatitis B associated Hepatocellular carcinoma in Victoria. for the Melbourne collaboration for the study of Hepatocellular carcinoma. Intern Med J. 2013 May;43(5):501-6.

 

Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, Dev A, Rode A, Bailey M, Cheung W, Kemp W, Roberts SK; Melbourne Liver Group. Radiofrequency ablation versus resection for the treatment of early stage hepatocellular carcinoma: a multicenter Australian study. Scand J Gastroenterol. 2015 May;50(5):567-76.

 

Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser S, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A. Sorafenib in the treatment of hepatocellular carcinoma: A multi-centre real-world study. Scand J Gastro 2016. 2016 Aug;51(8):979-85.

 

Hong TP, Gow P, Fink M, Dev A, Roberts S, Nicoll A, Lubel J, Kronborg I, Arachchi N, Ryan M, Kemp W, Knight V, Farrugia H, Thursfield V, Desmond P, Thompson AJ, Bell S.  Novel Population-Based Study Finding Higher Than Reported Hepatocellular Carcinoma Incidence Suggests an Updated Approach is Needed. Hepatology 2016;63;4:1205-1212.

 

Sara Mgaieth, William Kemp, Paul Gow, Michael Fink, John Lubel, Amanda Nicoll, Britt Christensen, Thai Hong, Marno Ryan, Virginia Knight , Anouk Dev, Siddarth Sood, Sally Bell, Stuart K Roberts. Impact Of Viral Hepatitis Aetiology On Survival Outcomes In Hepatocellular Carcinoma: A Large Multi-Centre Cohort Study. J Viral Hepat. 2017 Nov;24(11):982-989

 

S. Bloom, W. Kemp, A. Nicoll, S. Roberts, P. Gow, A. Dev, S. Bell, S. Sood, I. Kronborg, V. Knight, D. Lewis, J. Lubel. Community liver stiffness measurement detects high rates of advanced fibrosis and predicts liver related events in hepatitis C. Journal of Hepatology. 2018 Sep;69(3):575-583

 

Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, Lubel JS, Kronborg I, Arachchi N, Ryan M, Kemp WW, Knight V, Sundararajan V, Desmond P, Thompson AJ, Bell SJ. Improved survival with hepatocellular carcinoma surveillance highlights the need for greater uptake: results of a prospective Australian population-based clinical study. Med J Aust. 2018 Oct 15;209(8):348-354.

 

Roberts SK, Gazzola A, Lubel J, Gow P, Bell S, Nicoll A, Dev A, Fink MA, Sood S, Knight V, Hong T, Paul E, Mishra G, Majeed A, Kemp W; Melbourne Liver Group. Treatment choice for early-stage hepatocellular carcinoma in real-world practice: impact of treatment stage migration to transarterial chemoembolization and treatment response on survival. Scand J Gastroenterol. 2018 Nov 5:1-8.

 

Tan NP, Majeed A, Roberts SK, Gow PJ, Hey P, Mah X, Goodwin M, Sood S, Lubel J, Nicoll A, Dev A, Bell SJ, Kemp W.  Comparable survival of ruptured and non-ruptured hepatocellular carcinoma in an Australian cohort. Med J Aust. 2020 Jan 25. doi: 10.5694/mja2.50483.

 

Mishra G, Dev A, Paul E, Cheung W, Koukounaras J, Jhamb A, Marginson B, Lim BG, Simkin P, Borsaru A, Burnes J, Goodwin M, Ramachandra V, Spanger M, Lubel J, Gow P, Sood S, Thompson A, Ryan M, Nicoll A, Bell S, Majeed A, Kemp W, Roberts SK. Melbourne Liver Group. Prognostic role of alpha-fetoprotein in patients with hepatocellular carcinoma treated with repeat transarterial chemoembolisation. BMC Cancer. 2020 May 29;20(1):483. doi: 10.1186/s12885-020-06806-4.

 

French J, van der Mei I, Simpson S Jr, Ng J, Angus P, Lubel J, Nicoll A, Sood S, Roberts SK, Kemp W, Arachchi N, Dev A, Thompson A, Gow PJ. Increasing prevalence of primary biliary cholangitis in Victoria, Australia. J Gastroenterol Hepatol. 2020 Apr;35(4):673-679.

 

Hirsch RD, Mills C, Sawhney R, Sood S, Bird V, Mishra G, Dev A, Kemp W, Lubel J, Roberts SK, Gow P, Nicoll AJ. SIRT compared to DEB-TACE for Hepatocellular Carcinoma - a Real-World Study (The SITAR study). J Gastrointest Cancer. 2021 52(3): 907-914

 

Pham A, Vaz K, Ardalan Z, Sinclair M, Apostolov R, Gardner S, Majeed A, Mishra G, Kam N, Patwala K, Kutaiba N, Arachchi N, Bell S, Dev A, Lubel J, Nicoll A, Sood S, KempW, Roberts S, Fink M, TestroA, Angus P, Gow P. Clinical outcomes of patients with two small hepatocellular carcinomas. World J Hepatol. 2021 Oct 27;13(10):1439-1449

 

Kemp W, Majeed A, Mitchell J, Majumdar A, Tse E, Skoien R, Croagh D, Dev A, Gao H, Weltman M, Craig P, Stuart K, Cheng W, Edmunds S, Lee E, Sood S, Metz A, Thompson A, Sinclair M, Beswick L, Nicoll A, Riordan S, Braund A, Muller K, MacQuillan G, Sandanayake N, Shackel N, Roberts SK. Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study. Liver Int. 2021 Dec;41(12):2934-2943

 

Patwala K, Prince DS, Celermajer Y, Alam W, Paul E, Strasser SI, McCaughan GW, Gow P, Sood S, Murphy E, Roberts S, Freeman E, Stratton E, Davison SA, Levy MT, Clark-Dickson M, Nguyen V, Bell S, Nicoll A, Bloom A, Lee AU, Ryan M, Howell J, Valaydon Z, Mack A, Liu K, Dev A. Lenvatinib for the treatment of hepatocellular carcinoma-a real-world multicenter Australian cohort study. Hepatol Int. 2022 Aug 25. doi: 10.1007/s12072-022-10398-5.

 

Braude. M, Roberts. S, Majeed. A, Lubel. J, Prompen. J, Dev. A, Sievert. W, Bloom. S, Gow. P, Kemp. W. Liver stiffness (Fibroscan®) is a predictor of all-cause mortality in people with non-alcoholic fatty liver disease. Liver International 2022